Home › Long COVID › Missouri › St. Louis
Long COVID clinical trials in St. Louis, MO
3 studies for Long COVID are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
RecruitingPhase 3
- Research Site, St Louis
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
RecruitingObservational studyHealthy volunteers welcome
- Washington University in Saint Louis Department of Emergency Medicine, Emergency Care Research Core, St Louis
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RecruitingPhase 3
- St. Louis Children's Hospital, St Louis
- Washington University School of Medicine, St Louis
About Long COVID
Anyone who has had COVID-19 can have long-lasting symptoms, know as long COVID. Learn about the symptoms and how to manage them, diagnosis, and prevention.
More about Long COVID on MedlinePlus
Long COVID trials in other cities
- New York City, NY17 studies
- Houston, TX14 studies
- Chicago, IL12 studies
- Washington, DC12 studies
- Boston, MA11 studies
- Baltimore, MD11 studies
- Hialeah, FL8 studies
- Durham, NC8 studies
- San Francisco, CA8 studies
- Atlanta, GA7 studies
- San Diego, CA7 studies
- Miami, FL7 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer68 studies
- Breast Cancer63 studies
- Metastatic Cancer52 studies
- Cancer (all types)51 studies
- Colorectal Cancer51 studies
- Prostate Cancer45 studies
- Ovarian Cancer37 studies
- Lung Cancer37 studies
- Pancreatic Cancer33 studies
- Head and Neck Squamous Cell Carcinoma32 studies
- Endometrial Cancer29 studies
- Multiple Myeloma26 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.